Search hospitals > Minnesota > Sandstone
Essentia Health Sandstone
Claim this profileSandstone, Minnesota 55072
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Tumors
112 reported clinical trials
2 medical researchers
Summary
Essentia Health Sandstone is a medical facility located in Sandstone, Minnesota. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Essentia Health Sandstone is involved with conducting 112 clinical trials across 278 conditions. There are 2 research doctors associated with this hospital, such as Bret E. Friday and Bret EB Friday.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Bret E. FridayEssentia Health Cancer Center5 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
104 reported clinical trials
174 drugs studied
Bret EB FridayEssentia Health - Deer River Clinic5 years of reported clinical research
Studies Glioblastoma
Studies Cognitive Impairment
2 reported clinical trials
1 drug studied
Clinical Trials running at Essentia Health Sandstone
Breast Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Bladder Cancer
Diffuse Large B-Cell Lymphoma
Cutaneous Melanoma
Rectal Cancer
Follicular Lymphoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Support Program
for Breast Cancer
This study is evaluating whether a support program may help breast cancer patients take their medication correctly.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Essentia Health Sandstone?
Essentia Health Sandstone is a medical facility located in Sandstone, Minnesota. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Essentia Health Sandstone is involved with conducting 112 clinical trials across 278 conditions. There are 2 research doctors associated with this hospital, such as Bret E. Friday and Bret EB Friday.